This is a preview of subscription content, log in via an institution to check access.
References
Elmaagacli AH, Basoglu S, Peceny R et al. Improved disease-free-survival after transplantation of peripheral blood stem cells as compared with bone marrow from HLA-identical unrelated donors in patients with first chronic phase chronic myeloid leukemia. Blood 2002; 99: 1130–1135.
Mohty M, Kuentz M, Michallet M et al. Chronic graft-versus-host disease after allogeneic blood stem cell transplantation: long term results of a randomized study. Blood 2002; 100: 3128–3134.
Pistillo MP, Tazzari PL, Bonifazi F et al. Detection of a novel specificity (CTLA-4) in ATG/TMG globulin and sera from ATG-treated leukemic patients. Transplantation 2002; 73: 1295–1302.
Bacigalupo A, Lamparelli T, Guidi S et al. Antithymocyte globulin for graft-versus-host disease prophylaxis in transplants from unrelated donors: 2 randomized studies from Gruppo Italiano Trapianti Midollo Osseo (GITMO). Blood 2001; 98: 2942–2947.
Remberger M, Svahn BM, Hentschke P et al. Effect on cytokine-release and graft-versus-host disease of different anti-T cell antibodies during conditioning for unrelated haemopoietic stem cell transplantation. Bone Marrow Transplant 1999; 24: 823–830.
Kroger N, Zabelina T, Kruger W et al. In vivo T cell depletion with pretransplant anti-thymocyte globulin reduces graft-versus-host disease without increasing relapse in good risk myeloid leukemia patients after stem cell transplantation from matched related donors. Bone Marrow Transplant 2002; 29: 683–689.
Bonifazi F, Bandini G, Rondelli D et al. Reduced incidence of GVHD with low-dose rabbit ATG in the preparative regimen for unrelated bone marrow transplants in CML. Bone Marrow Transplant 2003; 32: 237–242.
Schetelig J, Borhauser M, Kiehl M et al. Reduced intensity conditioning with busulfan and fludarabine with or without antithymocyte globulin in HLA-identical sibling transplantation – a retrospective analysis. Bone Marrow Transplant 2004; 33: 483–490.
Gratwohl A, Baldomero H, Urbano-Ispizua A . Transplantation in chronic myeloid leukemia. Lancet 2002; 359: 712–713.
Schleuning M, Gunther W, Tischer J et al. Dose-dependent effects of in vivo antithymocyte globulin during conditioning for allogeneic bone marrow transplantation from unrelated donors in patients with chronic phase CML. Bone Marrow Transplant 2003; 32: 243–250.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Bonifazi, F., Bandini, G., Stanzani, M. et al. In vivo T-cell depletion with low-dose ATG is effective in reducing cGVHD after peripheral blood stem cell myeloablative sibling transplants in CML: results from a prospective phase II study. Bone Marrow Transplant 35, 1025–1026 (2005). https://doi.org/10.1038/sj.bmt.1704940
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.bmt.1704940
- Springer Nature Limited
This article is cited by
-
Questions concerning tyrosine kinase-inhibitor therapy and transplants in chronic phase chronic myeloid leukaemia
Leukemia (2022)
-
Rabbit ATG/ATLG in preventing graft-versus-host disease after allogeneic stem cell transplantation: consensus-based recommendations by an international expert panel
Bone Marrow Transplantation (2020)
-
Effective prevention of GVHD using in vivo T-cell depletion with anti-lymphocyte globulin in HLA-identical or -mismatched sibling peripheral blood stem cell transplantation
Bone Marrow Transplantation (2014)
-
Intensification of GVHD prophylaxis with low-dose ATG-F before allogeneic PBSC transplantation from HLA-identical siblings in adult patients with hematological malignancies: results from a retrospective analysis
Bone Marrow Transplantation (2012)
-
Fludarabine/i.v. BU conditioning regimen: myeloablative, reduced intensity or both?
Bone Marrow Transplantation (2008)